Real-Life Clinical Data of Cabozantinib for Unresectable Hepatocellular Carcinoma

Real-Life Clinical Data of Cabozantinib for Unresectable Hepatocellular Carcinoma

Introduction: Cabozantinib has been approved by the European Medicine Agency (EMA) for hepatocellular carcinoma (HCC) previously treated with sorafenib. Cabozantinib is also being tested in combination with immune checkpoint inhibitors in the frontline setting. Real-life clinical data of cabozantini...

Full description

Bibliographic Details
Main Authors: Francesco Tovoli, Vincenzo Dadduzio, Stefania De Lorenzo, Lorenza Rimassa, Gianluca Masi, Massimo Iavarone, Fabio Marra, Ingrid Garajova, Maria Pia Brizzi, Bruno Daniele, Franco Trevisani, Carlo Messina, Francesco Di Clemente, Sara Pini, Giuseppe Cabibbo, Alessandro Granito, Mario Domenico Rizzato, Vittorina Zagonel, Giovanni Brandi, Tiziana Pressiani, Piera Federico, Caterina Vivaldi, Irene Bergna, Claudia Campani, Fabio Piscaglia
Format: Article
Language:English
Published: Karger Publishers 2021-06-01
Series:Liver Cancer
Subjects:
hepatocellular carcinoma
cabozantinib
sorafenib
tyrosine kinase inhibitors
outcome
Online Access:https://www.karger.com/Article/FullText/515551

Internet

https://www.karger.com/Article/FullText/515551

Similar Items